Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


WKN: A2DJR8 / Symbol: FLML / Name: Avadel / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Avadel Pharmaceuticals plc ADR Stock

The community is currently still undecided about Avadel Pharmaceuticals plc ADR with 1 Buy predictions and 0 Sell predictions.
As a result the target price of 23 € shows a very positive potential of 52.32% compared to the current price of 15.1 € for Avadel Pharmaceuticals plc ADR.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Avadel Pharmaceuticals plc ADR stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Avadel Pharmaceuticals plc ADR in the next few years

M***** P*******
W********* I********* f** t** n*** y****
C******** o* t** e**********
G***** c******* t* c**********
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Avadel Pharmaceuticals plc ADR vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Avadel Pharmaceuticals plc ADR - - - - - - -
Valneva SE -4.610% -9.375% -8.356% -48.834% -28.245% -70.652% 0.795%
Nanobiotix -0.740% -7.531% -27.720% 5.435% -24.455% -62.374% -48.677%
Transgene S.A. 0.170% -5.477% -6.646% -38.115% -9.851% -56.857% -58.201%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-02

Upon examining the financials of Avadel Pharmaceuticals, a company operating in the Biotechnology & Medical Research industry under the US stock symbol FLML, it is apparent that the company has faced financial challenges over the past few years. The main striking points are the absence of reported revenue, significant net losses, and a negative total stockholder equity. However, the company has a strong cash position which may offer some cushioning against financial difficulties. This article will carefully analyze the financial strengths and weaknesses of Avadel Pharmaceuticals, offering insights into the company's current financial status and future prospects.

Cash and Short-term Investments: Avadel Pharmaceuticals maintains a substantial cash position, with $73,981,000 at the end of 2022, up from $50,708,000 in 2021. Additionally, the company holds $22,518,000 in short-term investments, reflecting their ability to secure liquid assets that could be utilized for research and development, debt servicing, or potential acquisitions.

Net Working Capital: Despite facing losses in recent years, Avadel Pharmaceuticals boasts a positive net working capital of $45,050,000 as of 2022, up from a significant $171,490,000 in 2021. This indicates that the company has enough liquid assets to cover its short-term liabilities, which is crucial in maintaining financial stability.